Risk of Inappropriately Timed Live Vaccination After Pediatric Cardiovascular Surgery

Area of Science:

• Pediatric cardiology
• Immunology
• Vaccinology

Background:

• Live vaccine administration timing is critical for efficacy, with recommendations to delay post-blood product transfusion.
• Infants aged 5-12 months undergoing cardiac surgery requiring blood products may face vaccination schedule disruptions.
• Current guidelines from the American Academy of Pediatrics (AAP), Advisory Committee on Immunization Practices (ACIP), and Centers for Disease Control and Prevention (CDC) advise specific delays.

Purpose of the Study:

• To determine the risk of inappropriate live vaccination timing in pediatric patients post-cardiovascular surgery.
• To assess the incidence of live vaccine administration within recommended delay periods after receiving blood products.

Main Methods:

• Retrospective chart review of 345 pediatric patients (5-12 months old) undergoing cardiovascular surgery.
• Analysis included patients who received packed red blood cells (PRBCs) and/or platelets during admission.
• Primary endpoint: incidence of live vaccine administration within 7 months of PRBCs/platelets.

Main Results:

• 67% (n=230) of the 345 included patients received live vaccines inappropriately after transfusion.
• A significant proportion of pediatric cardiac surgery patients experienced non-compliance with vaccination guidelines.

Conclusions:

• Infants undergoing cardiac surgery (5-12 months) are at high risk for improper live vaccine timing.
• A substantial percentage of these children received live vaccines inconsistently with AAP, ACIP, and CDC recommendations.
• Provider and patient education may be necessary to improve vaccination practices.